- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07816341
F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia
A Phase 1 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of F182112 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
This is an open-label, phase I clinical study of F182112 in patients with relapsed or refractory autoimmune hemolytic anemia (AIHA). Participants will receive F182112 at different dose levels. The main purpose of the study is to evaluate the safety and tolerability of F182112 and to identify an appropriate dose for further clinical development.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Lele Zhang
- Telefoonnummer: 8602223908328
- E-mail: zhanglele@ihcams.ac.cn
Studie Locaties
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 301617
- Werving
- Red Blood Cell Diseases Center and Regenerative Medicine Center
-
Contact:
- Lele Zhang
- Telefoonnummer: 02223608328
- E-mail: zhanglele@ihcams.ac.cn
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18-75 years.
- Diagnosis of AIHA according to established Chinese or international criteria, including warm AIHA, mixed AIHA, cold agglutinin disease, or Evans syndrome.
- Refractory to multiple lines of therapy, meeting all of the following: HGB <100 g/L with evidence of hemolytic anemia; Prior treatment with ≥2 immunosuppressive therapies, including a CD20 monoclonal antibody; Glucocorticoid treatment for ≥3 months, unless contraindicated or intolerable; Adequate prior CD20 monoclonal antibody treatment (≥4 doses of 100 mg or 375 mg/m², or 2 doses of 1,000 mg).
- ECOG performance status ≤2.
- Participants and their partners agree to use effective contraception from informed consent through 1 year after study treatment.
- Written informed consent must be obtained before any study-specific screening procedures.
Exclusion Criteria:
- Diagnosed lymphoproliferative malignancy.
- Secondary AIHA caused by drugs or infection.
- Congenital immunodeficiency or other inherited or acquired hemolytic disorders.
- Prior organ or hematopoietic stem cell transplantation.
- New thrombotic events or organ infarction within 6 months before enrollment.
- Prior BCMA-targeted therapy within 6 months before enrollment.
- Any of the following prior treatments within the specified washout periods: Anti-CD20 monoclonal antibody within 12 weeks; Sutimlimab or other approved biologic therapy within 5 half-lives; Plasma exchange within 4 weeks; Splenectomy within 12 weeks.
- Any of the following cardiovascular conditions: LVEF ≤45%; Active cardiac disease or NYHA class III/IV heart failure; Clinically significant arrhythmia requiring treatment, except atrial fibrillation or paroxysmal supraventricular tachycardia; QTc ≥450 ms in males or ≥470 ms in females; Myocardial infarction, coronary artery bypass grafting, or coronary stent placement within 6 months; Other clinically significant cardiac disease considered unsuitable by the investigator.
- Unstable systemic disease, including severe hepatic or renal disease requiring treatment.
- History of another primary malignancy within 5 years before screening, except adequately treated non-melanoma skin cancer, carcinoma in situ, or other malignancies without recurrence for ≥5 years.
- Major surgery within 4 weeks before screening if considered unsuitable for enrollment by the investigator.
- Uncontrolled active fungal, viral, bacterial, tuberculosis, or other infection, or infection requiring intravenous antimicrobial therapy.
- Active or clinically significant HBV, HCV, HIV, or syphilis infection
- Live-virus vaccination within 4 weeks before enrollment.
- Participation in another interventional clinical study within 5 half-lives of the investigational treatment before screening, or planned use of another investigational treatment during this study.
- Pregnant or breastfeeding women.
- Psychiatric disorders, impaired consciousness, or central nervous system disorders, including a history of epilepsy or Parkinson's disease.
- Known hypersensitivity to any component of F182112.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia
F182112 is a recombinant humanized anti-BCMA/CD3 bispecific antibody for injection. By binding to CD3 receptors on T cells, F182112 can effectively deplete BCMA-expressing B cells and plasma cells in vivo, thereby alleviating the clinical manifestations of autoimmune diseases. |
The dose-escalation phase will evaluate three sequential target dose levels of F182112: 30 μg/kg, 90 μg/kg, and 180 μg/kg, using a standard 3+3 design. F182112 will be administered intravenously using a priming dose followed by a target dose. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of adverse events
Tijdsspanne: 28 days post the last dose treatment
|
Use Common Terminology Criteria for Adverse Events (CTCAE) Version 6 to assess the adverse event |
28 days post the last dose treatment
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Jun Shi, Institute of Hematology & Blood Diseases Hosptial, Chinese Academy of Medical Science and Peking Union Medical College Principal Investigator
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IIT2026108
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .